Written records of investigation of a drug complaint do not include the findings of the investigation and the follow-up.
Inspection Record
Microvascular Tissue, Inc — FDA 483 Findings
Inspectors Garrad R Poole · Richard T RiggieThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
The identity of each component of a drug product is not verified by conducting at least one test to verify the identity, using specific identity tests ifthey exist.
There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Baxalta Belgium Manufacturing S.A.2019-05-31 · US FDASimilar to finding 4 There is a failure to thoroughly review a batch or any of its components to meet any of its specifications Whether or not the batch has been already…
- Mylan Laboratories Ltd.2016-09-14 · US FDASimilar to finding 1 Written records of investigation of a drug complaint do not include the findings of the investigation and the follow-up.
- Natco Pharma Limited2023-10-18 · US FDASimilar to finding 2 Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity…
- Fareva Amboise2025-09-16 · US FDASimilar to finding 2 Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity…
- Pharmathen International S.A.2025-11-21 · US FDASimilar to finding 2 Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity…
A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.